Expression of EpCam and villin in Barrett's esophagus and in gastric cardia

Disease Markers

Volumn 24, Issue 6, 2008, Pages 287-292

  Anders, Mario ^a   Sarbia, Mario ^b   Grotzinger, Carsten ^a   Meining, Alexander ^c   Hofler, Heinz ^c   Wiedenmann, Bertram ^a   Rosch, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Barrett; Biomarker; Dysplasia; Endoscopy; EpCam; Metaplasia; Neoplasia; Villin

Indexed keywords

BIOLOGICAL MARKER; EPITHELIAL CELL ADHESION MOLECULE; VILLIN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CARDIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL DETECTION; SQUAMOUS EPITHELIUM; STOMACH MUCOSA;

EID: 49149129275     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/679893     Document Type: Article

References (32)

1. R.E. Sampliner, Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology, Am J Gastroenterol 93 (1998), 1028-1032.
2. W.J. Blot and J.K. McLaughlin, The changing epidemiology of esophageal cancer, Semin Oncol 26 (1999), 2-8.
3. J. Powell and C.C. McConkey, The rising trend in oesophageal adenocarcinoma and gastric cardia, Eur J Cancer Prev 1 (1992), 265-269.
4. J.F. Flejou, Barrett's oesophagus: from metaplasia to dysplasia and cancer, Gut 54(Suppl 1) (2005), i6-12.
5. P. Sharma, T.G. Morales and R.E. Sampliner, Short segment Barrett's esophagus - the need for standardization of the definition and of endoscopic criteria, Am J Gastroenterol 93 (1998), 1033-1036.
6. R.E. Rudolph, T.L. Vaughan, B.E. Storer, R.C. Haggitt, P.S. Rabinovitch, D.S. Levine and B.J. Reid, Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus, Ann Intern Med 132 (2000), 612-620.
7. M.A. Kara and J.J. Bergman, Autofluorescence imaging and narrow-band imaging for the detection of early neoplasia in patients with Barrett's esophagus, Endoscopy 38 (2006), 627-631.
8. R. Keller, G. Winde, H.J. Terpe, E.C. Foerster and W. Domschke, Fluorescence endoscopy using a fluorescein-labeled monoclonal antibody against carcinoembryonic antigen in patients with colorectal carcinoma and adenoma, Endoscopy 34 (2002), 801-807.
9. S.Kumble, M.B. Omary, L.F. Fajardo and G. Triadafilopoulos, Multifocal heterogeneity in villin and Ep-CAM expression in Barrett's esophagus, Int J Cancer 66 (1996), 48-54.
10. A.J. MacLennan, M.B. Orringer and D.G. Beer, Identification of intestinal-type Barrett's metaplasia by using the intestine-specific protein villin and esophageal brush cytology, Mol Carcinog 24 (1999), 137-143.
11. R. Ouatu-Lascar, R.C. Fitzgerald and G. Triadafilopoulos, Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression, Gastroenterology 117 (1999), 327-335.
12. S.P. Regalado, Y. Nambu, M.D. Iannettoni, M.B. Orringer and D.G. Beer, Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas, Mol Carcinog 22 (1998), 182-189.
13. N.A. Wong, B.F. Warren, J. Piris, N. Maynard, R. Marshall and W.F. Bodmer, EpCAM and gpA33 are markers of Barrett's metaplasia, J Clin Pathol 59 (2006), 260-263.
14. M. Balzar, M.J. Winter, C.J. de Boer and S.V. Litvinov, The biology of the 17-1A antigen (Ep-CAM), J Mol Med 77 (1999), 699-712.
15. A. Bretscher and K. Weber, Villin: the major microfilament-associated protein of the intestinal microvillus, Proc Natl Acad Sci USA 76 (1979), 2321-2325.
16. rd ed. Stacey E. Mills (ed)., Lippincott Williams & Wilkins, Philadelphia 2007. In., 2007, pp. 589-602.
17. R.C. Haggitt, Barrett's esophagus, dysplasia, and adenocarcinoma, Hum Pathol 25 (1994), 982-993.
18. E. Montgomery, J.R. Goldblum, J.K. Greenson, M.M. Haber, L.W. Lamps, G.Y. Lauwers, A.J. Lazenby, D.N. Lewin, M.E. Robert, K. Washington, M.L. Zahurak and J. Hart, Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study, Hum Pathol 32 (2001), 379-388.
19. A.H. Ormsby, R.E. Petras, W.H. Henricks, T.W. Rice, L.A. Rybicki, J.E. Richter and J.R. Goldblum, Observer variation in the diagnosis of superficial oesophageal adenocarcinoma, Gut 51 (2002), 671-676.
20. B. H. von Rahden, H. J. Stein, F. Puhringer-Oppermann and M. Sarbia, c-myc amplification is frequent in esophageal adenocarcinoma and correlated with the upregulation of VEGF-A expression, Neoplasia 8 (2006), 702-707.
21. I.G. Martin, S.G. Cutts, K. Birbeck, S. Gray and P. Quirke, Expression of the 17-1A antigen in gastric and gastrooesophageal junction adenocarcinomas: a potential immunotherapeutic target? J Clin Pathol 52 (1999), 701-704.
22. N.K. Spurr, H. Durbin, D. Sheer, M. Parkar, L. Bobrow and W.F. Bodmer, Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI, Int J Cancer 38 (1986), 631-636.
23. A. Couvelard, J.M. Cauvin, D. Goldfain, A. Rotenberg, M. Robaszkiewicz and J.F. Flejou, Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology, Gut 49 (2001), 761-766.
24. A.H. Ormsby, J.R. Goldblum, T.W. Rice, J.E. Richter, G.W. Falk, M.F. Vaezi and T.L. Gramlich, Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach, Hum Pathol 30 (1999), 288-294.
25. H.M. El Zimaity and D.Y. Graham, Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens, Am J Gastroenterol 96 (2001), 1378-1382.
26. J.N. Glickman, H.Wang, K.M. Das, R.K. Goyal, S.J. Spechler, D. Antonioli and R.D. Odze, Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI, Am J Surg Pathol 25 (2001), 87-94.
27. I. Jovanovic, M. Tzardi, I.A. Mouzas, M. Micev, P. Pesko, T. Milosavljevic, M. Zois, M. Sganzos, G. Delides and P. Kanavaros, Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction, Histol Histopathol 17 (2002), 445-454.
28. I.A. Mohammed, C.J. Streutker and R.H. Riddell, Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia, Mod Pathol 15 (2002), 611-616.
29. M. Sarbia, A. Donner, C. Franke and H.E. Gabbert, Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and immunohistochemistry, Hum Pathol 35 (2004), 371-376.
30. K.M. Das, I. Prasad, S. Garla and P.S. Amenta, Detection of a shared colon epithelial epitope on Barrett epithelium by a novel monoclonal antibody, Ann Intern Med 120 (1994), 753-756.
31. D.T. McManus, A. Olaru and S.J. Meltzer, Biomarkers of esophageal adenocarcinoma and Barrett's esophagus, Cancer Res 64 (2004), 1561-1569.
32. C.P. Morales and S.J. Spechler, Intestinal metaplasia at the gastroesophageal junction: Barrett's, bacteria, and biomarkers, Am J Gastroenterol 98 (2003), 759-762.